Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Teva Pharmaceutical Industries Ltd. (TEVA : NYSE)
 
 • Company Description   
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.

Number of Employees: 36,830

 
 • Price / Volume Information   
Yesterday's Closing Price: $17.01 Daily Weekly Monthly
20 Day Moving Average: 9,371,926 shares
Shares Outstanding: 1,146.96 (millions)
Market Capitalization: $19,509.79 (millions)
Beta: 0.60
52 Week High: $22.80
52 Week Low: $12.47
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -4.28% -8.53%
12 Week 26.37% 7.94%
Year To Date -22.82% -27.71%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
124 DVORA HANEVI'a STREET
-
TEL AVIV,L3 6944020
ISR
ph: 972-3914-8213
fax: 972-3923-4050
tevair@tevapharm.com http://www.tevapharm.com
 
 • General Corporate Information   
Officers
Richard D. Francis - President; Chief Executive Officer and Director
SolJ. Barer - Chairman
Eli Kalif - Executive Vice President and Chief Financial Offic
Amir Weiss - Senior Vice President and Chief Accounting Officer
Rosemary A. Crane - Director

Peer Information
Teva Pharmaceutical Industries Ltd. (BGMR)
Teva Pharmaceutical Industries Ltd. (BBIO)
Teva Pharmaceutical Industries Ltd. (IPAH)
Teva Pharmaceutical Industries Ltd. (BRL)
Teva Pharmaceutical Industries Ltd. (BHC)
Teva Pharmaceutical Industries Ltd. (AKRXQ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-GENERIC DRG
Sector: Medical
CUSIP: 881624209
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/30/25
Share - Related Items
Shares Outstanding: 1,146.96
Most Recent Split Date: 7.00 (2.00:1)
Beta: 0.60
Market Capitalization: $19,509.79 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.69 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $2.42 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: 8.04% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/30/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 7.01
Trailing 12 Months: 6.97
PEG Ratio: 0.87
Price Ratios
Price/Book: 3.11
Price/Cash Flow: 5.06
Price / Sales: 1.17
EPS Growth
vs. Year Ago Period: 6.52%
vs. Previous Quarter: -30.00%
Sales Growth
vs. Year Ago Period: 1.89%
vs. Previous Quarter: -7.99%
ROE
06/30/25 - -
03/31/25 - 45.44
12/31/24 - 42.46
ROA
06/30/25 - -
03/31/25 - 6.95
12/31/24 - 6.65
Current Ratio
06/30/25 - -
03/31/25 - 1.03
12/31/24 - 0.98
Quick Ratio
06/30/25 - -
03/31/25 - 0.74
12/31/24 - 0.75
Operating Margin
06/30/25 - -
03/31/25 - 16.81
12/31/24 - 16.60
Net Margin
06/30/25 - -
03/31/25 - -7.74
12/31/24 - -9.91
Pre-Tax Margin
06/30/25 - -
03/31/25 - -3.15
12/31/24 - -7.76
Book Value
06/30/25 - -
03/31/25 - 5.47
12/31/24 - 4.74
Inventory Turnover
06/30/25 - -
03/31/25 - 2.39
12/31/24 - 2.29
Debt-to-Equity
06/30/25 - -
03/31/25 - 2.59
12/31/24 - 2.97
Debt-to-Capital
06/30/25 - -
03/31/25 - 72.14
12/31/24 - 75.23
 

Powered by Zacks Investment Research ©